Fairshter R D
Department of Medicine, University of California, Irvine.
Am J Med. 1988 Jul 29;85(1B):54-9. doi: 10.1016/0002-9343(88)90243-4.
Theophylline not only is a bronchodilator but also has other effects (inhibition of mediator release, enhancement of mucociliary clearance, enhancement of diaphragmatic contractility) that are potentially beneficial to asthmatic patients. Recent studies suggest that theophylline pharmacodynamics vary among asthmatic patients. However, on average, most of the total bronchodilatory response occurs at serum theophylline concentrations of 0 to 10 mg/liter. Additional (but less) bronchodilatation occurs at serum theophylline levels between 10 and 20 mg/liter. Pharmacodynamic relationships are not well established for other therapeutic effects of theophylline, such as attenuation of pharmacologically induced bronchoconstriction. An important feature of oral controlled-release theophylline therapy is timing of drug administration. Because airway reactivity increases and airway caliber decreases at night, it has been suggested that the greatest benefit is derived from theophylline when peak serum concentration is reached during the night or the early morning.
茶碱不仅是一种支气管扩张剂,而且还有其他作用(抑制介质释放、增强黏液纤毛清除功能、增强膈肌收缩力),这些作用对哮喘患者可能有益。最近的研究表明,哮喘患者之间茶碱的药效学存在差异。然而,平均而言,大部分支气管扩张总反应发生在血清茶碱浓度为0至10毫克/升时。在血清茶碱水平为10至20毫克/升之间会出现额外(但较少)的支气管扩张。对于茶碱的其他治疗作用,如减轻药物诱导的支气管收缩,药效学关系尚未完全确立。口服控释茶碱治疗的一个重要特点是给药时间。由于夜间气道反应性增加且气道管径减小,有人提出,当在夜间或清晨达到血清峰值浓度时,茶碱的获益最大。